AB Science (FRA:A8D)

€ 0.892 -0.007 (-0.78%) Market Cap: 60.59 Mil Enterprise Value: 70.43 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

AB Science SA Webcast with Experts in Sickle Cell Disease Transcript
Nov 30, 2023
AB Science SA Corporate Call Transcript
Mar 16, 2023
AB Science SA To Discuss the Masitinib Filing in the Treatment of ALS in Canada and Update on Clinical Program in all indications Call Transcript
Feb 28, 2022
AB Science SA Decisions On Clinical Studies With Masitinib- Corporate Call Transcript
Jun 03, 2021
AB Science SA Corporate Call Transcript
May 25, 2021
AB Science S.A. - Special Call Transcript
Dec 17, 2020
AB Science S.A. - Special Call Transcript
Dec 11, 2020
AB Science SA to Discuss Masitinib and Isoquercetin in COVID-19 - Conference Call Transcript
May 11, 2020
AB Science SA on Masitinib in Multiple Sclerosis - Conference Call Transcript
Mar 06, 2020
AB Science SA on Masitinib in Severe Asthma - Conference Call Transcript
Dec 02, 2019
AB Science SA on Indolent Systemic Mastocytosis - Conference Call Transcript
Nov 20, 2019

AB Science SA on Masitinib in Multiple Sclerosis - Conference Call Transcript

Mar 06, 2020 / 04:30PM GMT

Release Date Price: €8.27 (-6.66%)

Transcript

Operator

Good day, and welcome to the KOL call on masitinib in multiple sclerosis, boosted by AB Science. Today's conference is being recorded. At this time, I would like to turn the conference over to Alain Moussy. Please go ahead.

Alain Moussy

AB Science S.A. - Co-Founder, Chairman, President, CEO & Scientific Director

Welcome to our web conference led by AB Science to present masitinib results in primary progressive and non-active secondary progressive multiple sclerosis. My name is Alain Moussy. I'm the CEO of AB science, and I will have the pleasure to lead this web call with my distinguished associates and KOL and MS and also colleagues in AB Science.

We move -- let me present you the agenda. So the agenda is structured around 4 points. We'll briefly introduce the participants. We will review the landscape in multiple sclerosis and in particular, in progressive forms. And we will give, of course, the results of masitinib in the stage Phase IIb/III studies, and we'll answer your questions.

Next slide, the participants. So with me, the KOL

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.